Stockscreener 앱 받기
0.6848
0.97%
-0.0067
전일 마감가:
$0.6915
열려 있는:
$0.708
하루 거래량:
19,042
Relative Volume:
0.03
시가총액:
$3.38M
수익:
$14.64M
순이익/손실:
$-13.74M
주가수익비율:
-0.0942
EPS:
-7.27
순현금흐름:
$-5.04M
1주 성능:
-3.56%
1개월 성능:
+16.66%
6개월 성능:
+5.68%
1년 성능:
-88.00%
1일 변동 폭
$0.6606
$0.7113
1주일 범위
$0.6301
$0.72
52주 변동 폭
$0.3611
$9.079
Novabay Pharmaceuticals Inc Stock (NBY) Company Profile
명칭
Novabay Pharmaceuticals Inc
전화
510-899-8800
주소
2000 Powell Street, Suite 1150, Emeryville, CA
NBY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NBY
Novabay Pharmaceuticals Inc
|
0.6848 | 3.38M | 14.64M | -13.74M | -5.04M | -7.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.87 | 113.70B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.11 | 75.52B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
662.88 | 39.78B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.25 | 35.34B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.37 | 29.05B | 3.30B | -501.07M | 1.03B | -2.1146 |
Novabay Pharmaceuticals Inc Stock (NBY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2019-09-18 | 개시 | Ladenburg Thalmann | Buy |
| 2018-07-06 | 재확인 | H.C. Wainwright | Buy |
| 2017-11-15 | 재확인 | Laidlaw | Buy |
| 2017-06-05 | 개시 | ROTH Capital | Buy |
| 2017-03-27 | 개시 | Laidlaw | Buy |
| 2017-02-06 | 개시 | Rodman & Renshaw | Buy |
| 2016-03-07 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2015-12-14 | 재확인 | Maxim Group | Buy |
| 2015-04-30 | 재개 | Maxim Group | Buy |
| 2013-03-06 | 개시 | Ascendiant Capital Markets | Strong Buy |
| 2008-01-03 | 개시 | Dawson James | Speculative Buy |
모두보기
Novabay Pharmaceuticals Inc 주식(NBY)의 최신 뉴스
NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated at StockNews.com - Defense World
**NovaBay Pharmaceuticals Completes Asset Sale Transaction and Plans for Dissolution**** - Defense World
NovaBay Pharma’s Strategic Shift and Liquidation Plans - TipRanks
NovaBay Completes $11.5M Avenova Sale to PRN, Pursues Full Company Dissolution - StockTitan
NovaBay Pharmaceuticals Extends CEO’s Employment Agreement Until 2025 - Defense World
NovaBay extends CEO's contract through 2025 By Investing.com - Investing.com South Africa
NovaBay extends CEO's contract through 2025 - Investing.com India
NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated by Analysts at StockNews.com - Defense World
NovaBay Pharmaceuticals Completes Sale of Wound Care Product Trademarks and Inventory - Defense World
NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by Analysts at StockNews.com - Defense World
Novabay Pharmaceuticals Announces Board Changes - Marketscreener.com
NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Shares Cross Above 50 Day Moving Average – Should You Sell? - Defense World
NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by StockNews.com - Defense World
NovaBay Pharmaceuticals (NBY) Upgraded to Buy: Here's Why - Yahoo Finance
NovaBay Pharmaceuticals Adjourns Special Meeting Due to Insufficient Votes - Defense World
NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders - BioSpace
NovaBay Pharmaceuticals Delays Critical Vote on Avenova Sale and Company Dissolution Amid Vote Shortage - StockTitan
NovaBay®Pharmaceuticals, Inc. Launches NovaWipes Eyelid Wipes on Amazon.com - Marketscreener.com
NovaBay Pharmaceuticals (NYSE:NBY) Earns Hold Rating from Analysts at StockNews.com - Defense World
NBYNovaBay Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
NovaBay CEO Letter to Stockholders Urges a FOR Vote at Upcoming Reconvened Special Meeting - BioSpace
NovaBay Pharmaceuticals Urges Critical Vote on Eyecare Business Sale to PRN, Company Dissolution - StockTitan
NovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024 - BioSpace
NovaBay Postpones Key Vote on Asset Sale, Liquidation Plans Amid Low Turnout | NBY Stock News - StockTitan
NovaBay calls for affirmative vote on asset sale and dissolution - Investing.com
NovaBay calls for affirmative vote on asset sale and dissolution By Investing.com - Investing.com UK
NovaBay Pharmaceuticals Reports Q3 2024 Financials Amid Strategic Changes - TipRanks
NovaBay Pharmaceuticals Reports Third Quarter 2024 Results, Accepts Revised Offer to Sell Avenova Brand - Vision Monday
NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results - StockTitan
NovaBay accepts higher PRN offer, says Refresh deal no longer superior - MSN
NovaBay agrees to increased offer for eyecare unit - Investing.com
NovaBay agrees to increased offer for eyecare unit By Investing.com - Investing.com UK
NovaBay Pharmaceuticals Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase Price - StockTitan
NovaBay Pharmaceuticals : Signs Distribution Agreement With the Biopharm Group - Marketscreener.com
# NovaBay Pharmaceuticals Considers Acquisition Offer in Recent SEC Filing - Defense World
NovaBay Pharmaceuticals receives unsolicited offer from Refresh Acquisitions - MSN
NovaBay Pharmaceuticals Board Determines Unsolicited Offer is Superior to Asset Purchase Agreement with PRN Physician Recommended Nutriceuticals, LLC - StockTitan
NovaBay to sell Avenova assets - Healio
NovaBay Pharmaceuticals Signs Definitive Agreement to Sell Its Avenova AssetsVision Monday - Vision Monday
Novabay Pharmaceuticals Inc (NBY) Stock: A Year of Market Fluctuations - The InvestChronicle
Before You Invest, Make Sure You Check This Novabay Pharmaceuticals Inc (AMEX: NBY) Analysis - Stocks Register
Novabay Pharmaceuticals Inc (NBY)’s Market Momentum: Closing Strong at 0.70, Down -5.62 - The Dwinnex
NovaBay Pharmaceuticals, Inc. announced that it expects to receive $2.83 million in funding from Pioneer Pharma Pte. Ltd. and other investors. - Marketscreener.com
A new trading data show Novabay Pharmaceuticals Inc (NBY) is showing positive returns. - SETE News
Kuehn Law Encourages COFS, ARC, RFL, and NBY Investors to Contact Law Firm - PR Newswire
What's Going On With NovaBay Pharmaceuticals Shares Friday? - Benzinga
NBY’s price-to-free cash flow ratio: What it means for investors - US Post News
NovaBay sells Avenova brand to PRN for $9.5 million - Investing.com
PRN Nutriceuticals agreed to acquire Assets of Avenova Brand and Business of NovaBay Pharmaceuticals, Inc.. - Marketscreener.com
Novabay Pharmaceuticals Inc (NBY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.45%
5.38%
자본화:
|
볼륨(24시간):